KRAS

[Science Signaling] The authors found that glucocorticoid receptor was present in cytoplasmic KRAS-containing complexes and inhibited the activation of wild-type and oncogenic KRAS in mouse embryonic fibroblasts and human lung cancer A549 cells.

[Heliyon] Scientists investigated the effect and efficacy of 2-pyridin-4-yl methylene β-boswellic acid (PMBA) and 5-FU in combination therapy compared in the treatment of KRAS mutant colon cancer.

[Cell Reports Medicine] Investigators demonstrated that AXL was a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.

[Nucleic Acids Research] The authors showed that APE1 (apurinic/apyrimidinic endonuclease 1), a multifunctional DNA repair enzyme, is a G4-binding protein, and loss of APE1 abrogated the formation of stable G4 structures in cells.

[Cellular and Molecular Gastroenterology and Hepatology] Scientists discovered that non-cell autonomous oncogenic KRAS signaling reprogramed pancreatic fibroblasts, activating an inflammatory gene expression program.

[Communications Biology] Researchers used a humanized mouse model to show that while carboplatin plus pembrolizumab reduced tumor growth moderately and transiently, the addition of the tumor suppressor gene TUSC2, delivered systemically in nanovesicles, to this combination, eradicates tumors in the majority of animals.